Walter Duffy, MD
Psychiatry · Lincoln, NENPI 1093853368
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (37.8%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 21.3%. Reporting peaked in 2019 at $26,800 and has fallen 91.2% since, to $2,369 in 2025. Among psychiatry clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,085 payments — averaging $42.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$10K
- Ironshore Pharmaceuticals Inc.$10K
- Livanova USA, Inc.$7K
- Neurocrine Biosciences, Inc.$6K
- AbbVie$4K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- plus $8K from 30 others
Across 1,562 payments — averaging $4678.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Livanova USA, Inc.$2M
- Sage Therapeutics, LLC$870K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$712K
- Alkermes, Inc.$701K
- AbbVie$568K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$446K
- plus $2M from 22 others
What the payments were for
- Consulting fees$9,84021%
- Speaking & faculty fees$17,35038%
- Travel & lodging$4,1779%
- Food & beverage$14,10331%
- Education$4111%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Jornay PM 20mg capsules (Bottle of 100)$9,054
- VNS Therapy Symmetry Model 8103 Generator$6,484
- INGREZZA$5,550
- VRAYLAR$2,120
- Azstarys$480
How this compares
$45,881 in reported general payments places this provider in the 95th percentile of 160 psychiatry providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 116 | $391,500 |
| AristadaAripiprazole Lauroxil | 93 | $321,927 |
| IngrezzaValbenazine Tosylate | 33 | $261,394 |
| VraylarCariprazine Hcl | 183 | $251,909 |
| CaplytaLumateperone Tosylate | 97 | $164,796 |
| Abilify MaintenaAripiprazole | 49 | $137,073 |
| Invega TrinzaPaliperidone Palmitate | 12 | $104,011 |
| RexultiBrexpiprazole | 31 | $42,580 |
| SunosiSolriamfetol Hcl | 28 | $24,336 |
| LybalviOlanzapine/Samidorphan Malate | 15 | $23,945 |
| Lurasidone Hcl | 102 | $20,487 |
| NuedextaDextromethorphan Hbr/Quinidine | 13 | $19,304 |
| VyvanseLisdexamfetamine Dimesylate | 51 | $17,788 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 387 | $17,215 |
| Aripiprazole | 301 | $14,833 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza | $576 | $495,511128 claims |
| Alkermes, Inc.Aristada, Lybalvi | $9,777 | $345,871108 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $6,044 | $261,39433 claims |
| AbbVieVraylar | $3,730 | $251,909183 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $1,221 | $179,65380 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,566 | $164,79697 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Trintellix | $154 | $30,81678 claims |
| Axsome Therapeutics, Inc.Sunosi | $613 | $24,33628 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $106 | $19,30413 claims |
| MerckBelsomra | $94 | $13,69231 claims |
| Lilly USA, LLCOlanzapine | $13 | $6,126265 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 160 psychiatry providers in Nebraska.
Other psychiatry in Lincoln
- Dianna ClyneLincoln$19K
- Jeffrey CoffmanLincoln$18K
- Kelli BremerLincoln$13K
- Rajeev ChaturvediLincoln$6K
- Danielle BudaLincoln$5K
- Ryan SantinLincoln$2K
- Andi NgoLincoln$1K
- Jessica BuettnerLincoln$1K
- Sanat RoyLincoln$794
- William MichaelLincoln$289
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.